This is the authors' abstract. We don't add key points for this paper.
This is the first study to demonstrate that exogenous β-hydroxybutyrate supplementation attenuates metabolic syndrome (MetS) and identifies histone β-hydroxybutyrylation-mediated chromatin remodeling as one of the mechanisms to upregulate the transcription of the lipid catabolic genes, Hmgcs2, Cyp2d4, Cyp2e1, and Acaa1b. Our work constitutes a strong foundation for the use of 1,3-butanediol as an alternative epigenetic therapeutic for individuals who are physically unable to achieve the MetS lowering benefits of lifestyle modifications such as exercise and intermittent fasting.
No takes yet. Share an insight, caveat, or question.
Aryal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: